The Globe and Mail reports in its Wednesday, Nov. 6, edition that RBC Capital analyst Douglas Miehm has reaffirmed his "outperform" recommendation for DRI Healthcare. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm hiked his unit target by a loonie to $17. Analysts on average target the units at $19.58. Mr. Miehm says in a note: "While the announced royalty acquisition on sebetralstat revenues has a higher risk profile than the usual royalty transactions undertaken by DRI, we find the long duration of the asset (royalty receipts are anticipated to be collected through at least 2041, according to management) and strong cash-on-cash multiple (approximately 3.49 times; RBC estimate) along with a 13.6-per-cent IRR as attractive attributes. Overall portfolio duration is expected to increase from 9.9 years to 10.8 years. Ahead of the Q3/24 results (AMC 06-November), we have also updated our estimates to reflect changes to the outlook for assets held within DRI's portfolio." The Globe reported on Oct. 10 that Stifel analyst Justin Keywood was sticking with his "buy" call on DRI Healthcare. The units could then be had for $14.55.